PEGylation, or bioconjugation of a molecule with PEG (polyethylene glycol), is a proven drug delivery technology pioneered by Enzon. To date, Enzon's established technology and know-how have been used to develop eight marketed products with combined annual sales of over
In building a next generation of PEGylated products, Enzon has developed the industry leading releasable PEGylation technology utilizing its Customized Linker Technology, wherein PEG polymers are shed via a controlled release mechanism to release the intact parent drug. Releasable PEG linkers can not only provide a practical option to improve the pharmaceutical properties of parent molecules without the need for reengineering if the parent molecules are biologics, but can also be used as a way to predictably modify and release a wide range of therapeutic components. Further, releasable PEG linkers are designed to overcome the limitations of permanent PEGylation, such as diminished pharmacological properties of the modified molecule, and may result in reduced immunogenicity and optimized pharmacokinetics.
"PEGylation is a well-established drug delivery technology that has been shown to enhance the pharmaceutical properties of various drug molecules, resulting in improved products with demonstrated efficacy and dosing advantages for patients and healthcare providers," said Dr.
Enzon recently entered into collaboration agreements with
About Enzon's Customized PEGylation Linker Technology
PEGylation has successfully been used on various pharmaceutical compounds, including enzymes, peptides and antibodies, to improve their pharmaceutical properties through the chemical attachment of polyethylene glycol (PEG) using our Customized Linker Technology. PEGylation technology employs proprietary chemical linkers designed to either release the native molecule at a controlled rate or provide permanent linkage that will maximize inherent activity of the parent molecule. In some cases, PEGylation can render a compound therapeutically effective, whereas the unmodified form had only limited clinical utility.
This press release contains, or may contain, forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements that are purely historical, are forward-looking statements, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions.
Such forward-looking statements are based upon management's present expectations, objectives, anticipation, plans, hopes, beliefs, intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements. The results of preclinical data are not necessarily indicative of clinical efficacy. A more detailed discussion of these and other factors that could affect results is contained in Enzon's filings with the
Andrea Rabney Argot Partners212.600.1902 Email Contact Media Contact: Eliza Schleifstein Argot Partners212.600.1902 Email Contact
News Provided by Acquire Media